SCHEMBL4943473

SCHEMBL4943473

CCCCCc1ccc(C(=O)N2C/C(=N/OCc3ccccc3)C[C@H]2C(=O)Nc2ccc3c(c2)c2ccccc2n3CC)c(=O)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.40
KDM4E B2RXH2 8/20 0.40
MEN1 O00255 8/20 0.40
KMT2A Q03164 8/20 0.40
ALDH1A1 P00352 4/20 0.40
LMNA P02545 3/20 0.40
HPGD P15428 3/20 0.40
NPY5R Q15761 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
REV1 Q9UBZ9 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
POLB P06746 3/20 0.38
GAA P10253 1/20 0.38
CFTR P13569 5/20 0.38
NPSR1 Q6W5P4 2/20 0.38
USP2 O75604 1/20 0.38
ALPI P09923 1/20 0.38
RECQL P46063 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4943480 1.00 MAPT (0.40) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4936255 0.94 CFTR (0.42) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4936260 0.94 CFTR (0.42) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4945193 0.94 MAPT (0.42) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4945200 0.94 MAPT (0.42) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4943684 0.91 MAPT (0.43) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4942683 0.91 MAPT (0.43) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4942673 0.91 MAPT (0.43) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4949437 0.90 MAPT (0.40) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4949431 0.90 MAPT (0.40) MAPTKDM4EMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167318-A1 Pharmaceutically active pyrrolidine derivatives APPLIED RESEARCH SYSTEM ARS HOLDING N.V. (NL) 2008-07-10 US disclosed
US-7211601-B2 Pharmaceutically active pyrrolidine derivatives APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2007-05-01 US disclosed
EP-1268419-B1 PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS (AN) 2006-06-21 EP disclosed
EP-1268418-B1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS (AN) 2006-06-14 EP disclosed
US-7018988-B2 Pharmaceutically active pyrrolidine derivatives as Bax inhibitors APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2006-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167318-A1 Pharmaceutically active pyrrolidine derivatives OXTR, PRLHR, NR0B1 MAPT 4816/4885KDM4E 2451/4885MEN1 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.